J7321 HCPCS code: Hyaluronan or derivative, hyalgan, supartz or visco-3, for intra-articular injection, per dose
J7321 is the HCPCS Level II code for hyaluronan or derivative, hyalgan, supartz or visco-3, for intra-articular injection, per dose. In 2024 Medicare paid an average of $56.44 per service for J7321 across 321,248 services. Its Medicare coverage code is C (Carrier judgment): Coverage is decided by the Medicare contractor (MAC) case by case. The NCCI unit limit is 2 per day on outpatient hospital claims. Medicare volume rose 20% from 2022 to 2024 (267,714 to 321,248 services). In 2024, about 7,025 clinicians billed Medicare for J7321 for 54,924 beneficiaries; California, New York, Florida accounted for 41% of services.
Code details
| Field | Value |
|---|---|
| Section | J codes — Drugs administered other than oral method |
| Coverage code | C — Carrier judgment |
| Pricing indicator | 51 — Drug or biological (priced per ASP/average sales price rules) |
| BETOS category | O1E — Other drugs |
| Added | 2008-01-01 |
| Last action effective | 2024-01-01 |
Who bills J7321 (2024)
| Measure | Value |
|---|---|
| Clinicians billing (by place of service) | 7,025 |
| Medicare beneficiaries | 54,924 |
| States with claims | 51 |
| Share of services in top 3 states (California, New York, Florida) | 41% |
Counts only. Supplier and clinician names, contact lists and state-by-state detail are in Caduvo.
Medicare utilization for J7321, 2022–2024
| Year | Services | Beneficiaries | Avg. allowed | Avg. paid |
|---|---|---|---|---|
| 2022 | 267,714 | 47,794 | $74.77 | $58.56 |
| 2023 | 318,012 | 55,181 | $73.44 | $57.56 |
| 2024 | 321,248 | 54,924 | $72.25 | $56.44 |
States with the most J7321 services (2024)
| State | Services | Avg. paid |
|---|---|---|
| California | 64,390 | $56.81 |
| New York | 33,705 | $56.54 |
| Florida | 33,416 | $56.13 |
| Illinois | 26,396 | $56.93 |
| Texas | 20,138 | $56.18 |
NCCI unit limits (MUE)
| Claim type | Max units per day | Rationale |
|---|---|---|
| outpatient hospital claims | 2 | Anatomic Consideration |
| practitioner claims | 2 | Anatomic Consideration |
Medicare policy articles for this code
- A52420: Billing and Coding: Hyaluronans Intra-articular Injections of (Wellpoint Federal (MAC - Part A, MAC - Part B))
- A56157: Billing and Coding: Intraarticular Knee Injections of Hyaluronan (WPS Insurance Corporation (MAC - Part A, MAC - Part B))
- A59030: Billing and Coding: Hyaluronic Acid Injections for Knee Osteoarthritis (Palmetto GBA (MAC - Part A, MAC - Part B))
Covered diagnoses (17 ICD-10-CM codes)
The diagnoses most often listed as covered in the policy articles above:
| ICD-10-CM | Diagnosis | Articles listing it |
|---|---|---|
| M17.0 | Bilateral primary osteoarthritis of knee | 3 |
| M17.11 | Unilateral primary osteoarthritis, right knee | 3 |
| M17.12 | Unilateral primary osteoarthritis, left knee | 3 |
| M17.2 | Bilateral post-traumatic osteoarthritis of knee | 3 |
| M17.31 | Unilateral post-traumatic osteoarthritis, right knee | 3 |
| M17.32 | Unilateral post-traumatic osteoarthritis, left knee | 3 |
| M17.4 | Other bilateral secondary osteoarthritis of knee | 3 |
| M17.5 | Other unilateral secondary osteoarthritis of knee | 3 |
| M17.9 | Osteoarthritis of knee, unspecified | 1 |
| M19.011 | Primary osteoarthritis, right shoulder | 1 |
Showing 10 of 17. The full list, non-covered diagnoses and CSV export are in Caduvo.
What changed for J7321
- 2008-01-01: J7321 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code J7321?
J7321 is the HCPCS Level II code for hyaluronan or derivative, hyalgan, supartz or visco-3, for intra-articular injection, per dose. Short descriptor: "Hyalgan supartz visco-3 dose".
How much does Medicare pay for J7321?
In 2024, the average Medicare payment was $56.44 per service (average allowed $72.25).
Does Medicare cover J7321?
Coverage code C — Carrier judgment. Coverage is decided by the Medicare contractor (MAC) case by case.
Which diagnoses support coverage for J7321?
Medicare policy articles that cite J7321 list 17 covered ICD-10-CM diagnosis codes across 3 articles. The most cited include M17.0 (Bilateral primary osteoarthritis of knee), M17.11 (Unilateral primary osteoarthritis, right knee), M17.12 (Unilateral primary osteoarthritis, left knee). A listed diagnosis is necessary but not sufficient; the policy's other criteria still apply.
How many units of J7321 can be billed per day?
2 on outpatient hospital claims; 2 on practitioner claims (NCCI medically unlikely edits).
Related J73 codes
- J7300 — Intrauterine copper contraceptive (paragard)
- J7301 — Levonorgestrel-releasing intrauterine contraceptive system (skyla), 13.5 mg
- J7302 — Levonorgestrel-releasing intrauterine contraceptive system, 52 mg
- J7303 — Contraceptive supply, hormone containing vaginal ring, each
- J7304 — Contraceptive supply, hormone containing patch, each
- J7306 — Levonorgestrel (contraceptive) implant system, including implants and supplies
- J7307 — Etonogestrel (contraceptive) implant system, including implant and supplies
- J7308 — Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg)
- J7309 — Methyl aminolevulinate (mal) for topical administration, 16.8%, 1 gram
- J7310 — Ganciclovir, 4.5 mg, long-acting implant
- J7311 — Injection, fluocinolone acetonide, intravitreal implant (retisert), 0.01 mg
- J7312 — Injection, dexamethasone, intravitreal implant, 0.1 mg
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under J7321
- Watch J7321 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for J7321
Compiled by Caduvo from public CMS (Medicare) records, HCPCS release October 2026. Fees are Medicare allowables, not commercial rates. Not reviewed or endorsed by CMS. Not billing or legal advice. Report an error. Data and corrections policy.